JSR Partners with Hokkaido University for Production and Sales of Functional Lipids for Lipid Nanoparticle DDS
Corporate
Tokyo, Japan - June 19, 2023 - JSR Corporation (JSR) is pleased to announce that it has signed a partnership agreement with Hokkaido University for the production, sales and marketing of functional lipids for lipid nanoparticles * 1, which is one of the drug delivery systems (DDS * 2).
Professor Hideyoshi Harashima, Assistant Professor Yusuke Sato, and others from Hokkaido University have developed the functional lipid CL4H6 and it has been reported that lipid nanoparticles with it demonstrated superior performance in various modalities * 3 such as mRNA vaccines, pharmaceuticals, nucleic acid medicines and genome editing. JSR has conducted research and development of next-generation DDS technology, while expanding its life sciences business in diagnostic reagent materials, bioprocess material and CRO/CDMO solutions. Together, the mass production technology for CL4H6 under site standards that follow ICH Q7 * 4 concepts were successfully developed to provide the market with high-quality lipids.
JSR aims to realize innovations that lead to new products and services needed in a healthy society by supporting pharmaceutical companies accelerating clinical development through advancements in research.
*1 Lipid nanoparticles: Nanoparticles composed mainly of lipids and with a diameter of approximately 10 to 1000 nm. As a non-viral DDS technology, it is used to deliver mRNA vaccines/medicines and nucleic acid medicines
*2 DDS: A generic term for technologies that deliver drugs to specific parts of the body and are used to control the pharmacokinetics of drugs to improve the therapeutic effect or reduce side effects
*3 Modalities: A classification of therapeutic measures such as small molecule drugs, antibody drugs, nucleic acid drugs, cell therapy, gene cell therapy and gene therapy
*4 ICH Q7: Good Manufacturing Practice (GMP) guidelines for drug substances
Professor Hideyoshi Harashima, Assistant Professor Yusuke Sato, and others from Hokkaido University have developed the functional lipid CL4H6 and it has been reported that lipid nanoparticles with it demonstrated superior performance in various modalities * 3 such as mRNA vaccines, pharmaceuticals, nucleic acid medicines and genome editing. JSR has conducted research and development of next-generation DDS technology, while expanding its life sciences business in diagnostic reagent materials, bioprocess material and CRO/CDMO solutions. Together, the mass production technology for CL4H6 under site standards that follow ICH Q7 * 4 concepts were successfully developed to provide the market with high-quality lipids.
JSR aims to realize innovations that lead to new products and services needed in a healthy society by supporting pharmaceutical companies accelerating clinical development through advancements in research.
*1 Lipid nanoparticles: Nanoparticles composed mainly of lipids and with a diameter of approximately 10 to 1000 nm. As a non-viral DDS technology, it is used to deliver mRNA vaccines/medicines and nucleic acid medicines
*2 DDS: A generic term for technologies that deliver drugs to specific parts of the body and are used to control the pharmacokinetics of drugs to improve the therapeutic effect or reduce side effects
*3 Modalities: A classification of therapeutic measures such as small molecule drugs, antibody drugs, nucleic acid drugs, cell therapy, gene cell therapy and gene therapy
*4 ICH Q7: Good Manufacturing Practice (GMP) guidelines for drug substances